Overcoming Barriers to Pediatric Glomerular Disease Clinical Trials

Pediatric nephrologists are working to increase the inclusion of children in clinical trials for glomerular diseases, moving away from the historical practice of relying solely on adult data. Experts note that increased research participation provides children with better safeguards and access to targeted therapies.
Why it matters
Improving pediatric clinical trial access is essential for developing safe and effective treatments specifically tailored to children's physiological needs.
Children with glomerular diseases have historically had fewer therapies developed and tested on their behalf than adults, leaving pediatric nephrologists to extrapolate safety and efficacy from adult data. As targeted agents move through adult pipelines, pediatric glomerular disease clinical trials are beginning to catch up.
Myda Khalid, MD, of Riley Hospital for Children at Indiana University, and Scott Wenderfer, MD, PhD, of BC Children’s Hospital and the University of British Columbia, co-chairs of the International Society of Glomerular Disease (ISGD) GD-Kids working group, spoke with HCPLive about the obstacles and how the field is addressing them.¹
What Has Held Back Pediatric Glomerular Disease Trials?
Wenderfer pointed to a longstanding tendency to protect children from research, which effectively barred them from trials. As a result, pediatric nephrology practice has largely relied on adapting adult safety and efficacy findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in